MX370252B - Silibina para el tratamiento de alteraciones oxidativas metabolicas en pacientes con esteatohepatitis no alcoholica (nash). - Google Patents

Silibina para el tratamiento de alteraciones oxidativas metabolicas en pacientes con esteatohepatitis no alcoholica (nash).

Info

Publication number
MX370252B
MX370252B MX2015013409A MX2015013409A MX370252B MX 370252 B MX370252 B MX 370252B MX 2015013409 A MX2015013409 A MX 2015013409A MX 2015013409 A MX2015013409 A MX 2015013409A MX 370252 B MX370252 B MX 370252B
Authority
MX
Mexico
Prior art keywords
patients
treatment
nash
silybin
alcoholic steatohepatitis
Prior art date
Application number
MX2015013409A
Other languages
English (en)
Other versions
MX2015013409A (es
Inventor
Carmelina Loguercio
Alessandro Federico
Paola Stiuso
Original Assignee
St Biochimico Italiano Giovanni Lorenzini S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St Biochimico Italiano Giovanni Lorenzini S P A filed Critical St Biochimico Italiano Giovanni Lorenzini S P A
Publication of MX2015013409A publication Critical patent/MX2015013409A/es
Publication of MX370252B publication Critical patent/MX370252B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02K—DYNAMO-ELECTRIC MACHINES
    • H02K41/00—Propulsion systems in which a rigid body is moved along a path due to dynamo-electric interaction between the body and a magnetic field travelling along the path
    • H02K41/02—Linear motors; Sectional motors
    • H02K41/03—Synchronous motors; Motors moving step by step; Reluctance motors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Electromagnetism (AREA)
  • Combustion & Propulsion (AREA)
  • Physics & Mathematics (AREA)
  • Emergency Medicine (AREA)
  • Power Engineering (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)

Abstract

La invención se relaciona con una composición para usarse en el tratamiento de alteraciones oxiclativas metabólicas en esteatohepatitis no alcohólica (NASH), en donde dicha composición comprende silibina, y en donde el tratamiento es administrado a pacientes que tienen un perfil lipídico alterado; los pacientes que tienen un perfil lipídico alterado muestran un valor alto de TBARS en la prueba de TBARS (marcador de peroxidación de lípidos) con respecto a sujetos sanos.
MX2015013409A 2013-03-20 2014-03-19 Silibina para el tratamiento de alteraciones oxidativas metabolicas en pacientes con esteatohepatitis no alcoholica (nash). MX370252B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000425A ITMI20130425A1 (it) 2013-03-20 2013-03-20 Composizione per il trattamento della sindrome metabolica e delle alterazioni metabolico-ossidative nei pazienti con steatoepatite non alcolica (nash)
PCT/EP2014/055499 WO2014147119A1 (en) 2013-03-20 2014-03-19 Silybin for the treatment of metabolic oxidative alterations in patients with non-alcoholic steatohepatitis (nash)

Publications (2)

Publication Number Publication Date
MX2015013409A MX2015013409A (es) 2016-06-24
MX370252B true MX370252B (es) 2019-12-06

Family

ID=48444504

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015013409A MX370252B (es) 2013-03-20 2014-03-19 Silibina para el tratamiento de alteraciones oxidativas metabolicas en pacientes con esteatohepatitis no alcoholica (nash).

Country Status (12)

Country Link
EP (1) EP2976075B1 (es)
JP (1) JP2016515540A (es)
BR (1) BR112015024181A2 (es)
DK (1) DK2976075T3 (es)
ES (1) ES2749192T3 (es)
HU (1) HUE045695T2 (es)
IT (1) ITMI20130425A1 (es)
MX (1) MX370252B (es)
PL (1) PL2976075T3 (es)
PT (1) PT2976075T (es)
RU (1) RU2694896C2 (es)
WO (1) WO2014147119A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105983016B (zh) 2015-03-23 2023-08-11 天士力医药集团股份有限公司 一种含有水飞蓟宾的药物组合
CN105983013A (zh) * 2015-03-23 2016-10-05 天士力制药集团股份有限公司 一种含有水飞蓟宾、葛根提取物的药物组合物
CN108685899A (zh) * 2017-04-07 2018-10-23 澳门科技大学 黄酮木脂素在制备用于治疗自身免疫炎症疾病的药物的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1215291B (it) * 1985-07-17 1990-01-31 Inverni Della Beffa Spa Complessi di flavanolignani con fosfolipidi, loro preparazione e relative composizioni farmaceutiche.
CN1513444A (zh) * 2003-07-11 2004-07-21 辽宁医联新药研究所 治疗代谢综合征的药物
CZ295149B6 (cs) * 2003-11-10 2005-06-15 Naturprodukt Cz Spol. S R. O. Potravinový doplněk na bázi silymarinu
CN101868243A (zh) * 2007-11-21 2010-10-20 客乐谐制药株式会社 芳香酶抑制剂
WO2010106083A1 (en) * 2009-03-16 2010-09-23 Genmedica Therapeutics Sl Combination therapies for treating metabolic disorders
EP2787988A4 (en) * 2011-12-08 2016-11-02 Metaproteomics Llc ADDED OIL COMPOSITIONS AND METHODS FOR ENHANCED HEALTH

Also Published As

Publication number Publication date
HUE045695T2 (hu) 2020-01-28
ES2749192T3 (es) 2020-03-19
MX2015013409A (es) 2016-06-24
PL2976075T3 (pl) 2020-03-31
WO2014147119A1 (en) 2014-09-25
JP2016515540A (ja) 2016-05-30
RU2015144870A (ru) 2017-04-25
BR112015024181A2 (pt) 2017-07-18
PT2976075T (pt) 2019-10-14
DK2976075T3 (da) 2019-10-14
EP2976075B1 (en) 2019-07-17
RU2694896C2 (ru) 2019-07-18
ITMI20130425A1 (it) 2014-09-21
EP2976075A1 (en) 2016-01-27

Similar Documents

Publication Publication Date Title
BR112015022047A8 (pt) uso de uma composição compreendendo nanopartículas contendo um fármaco da família limo e uma albumina
TWD187858S (zh) 呼吸回路之插管接頭
NZ726746A (en) Stable cannabinoid formulations
PH12016502355B1 (en) Pharmaceutical composition
BR112013025246A2 (pt) cateter e método para dispensação de um estímulo elétrico ao corpo
MY188139A (en) Sodium channel modulators for the treatment of pain
BR112013010556A2 (pt) métodos e composições adequadas para a promoção de uma pele saudável
BR112015021908A2 (pt) implante
BR112015023020A2 (pt) combinação de inibidor de egfr t790m e inibidor de egfr para o tratamento de câncer pulmonar de células não-pequenas
PH12016502352A1 (en) Pharmaceutical composition
TW201613578A (en) Pharmaceutical combinations
BR112015018270A2 (pt) composições que compreendem 15-ohepa e métodos de uso das mesmas
BR112015027477A8 (pt) bolus, seus usos, e kit
CU20140096A7 (es) Fenilimidazopirazoles sustituidos y su uso
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
MX2015013409A (es) Silibina para el tratamiento de alteraciones oxidativas metabolicas en pacientes con esteatohepatitis no alcoholica (nash).
MX2018004296A (es) Combinacion de un agonista selectivo de il-2rbeta y un agonista il-15 de accion prolongada.
EA201691299A1 (ru) Применение лахинимода для замедления прогрессирования болезни хантингтона
UA108975C2 (uk) Застосування співполімеру натрійкарбоксиметилцелюлози і госиполу в комплексній терапії пацієнтів з аутистичними розладами і когнітивними порушеннями
BR112015017432A2 (pt) métodos para o tratamento de indicações cardiovasculares
CL2016000397A1 (es) Tratamiento contra el cáncer
IN2014DN09383A (es)
BR112017012938A2 (pt) uso por via oral de uma composição e método para aprimorar a aparência da celulite
MX2015009414A (es) Agentes analgesicos oculares topicos.
BR112015020085A2 (pt) lipídeo que inibe a atividade do canal de nav1.9, composição, e kit

Legal Events

Date Code Title Description
FG Grant or registration